Ayr Wellness CEO David Goubert talks 'very balanced' Q2 earnings. (1:15) Focus on state footprints: Florida legalization, Ohio's nice rollout.... more

Jason Najum has covered the psychedelic space for a long time and contextualizes recent news around the FDA, MDMA, PTSD... more

On June 18 at our Seeking Alpha Investing Summit, Pablo Zuanic, Tim Seymour, and Julian Lin discussed how to best invest... more

Jerry Derevyanny and Julian Lin break down the current state of the cannabis sector (1:00). How companies are massaging their... more

Alex Carchidi talks why he's bullish on the cannabis sector, but not ready to buy stocks (1:15) except for IIPR... more

Verano (VRNOF) CEO George Archos and CIO Aaron Miles on recent earnings and why they're the most optimistic they've been... more

Mario Naric, CEO and Founder of Motif Labs, discusses being in the shakeout phase of cannabis in Canada (1:00). Staying... more

David Hart recently became CEO of The Cannabist Company and is focused on building a strong asset base in the... more

Bengal Capital's Jerry Derevyanny shares his evolving thoughts on 280E and the process of rescheduling cannabis (2:20). Some uncomfortable truths... more

Katie Neer and Hirsh Jain break down the dispiriting New York and California cannabis markets (3:00). What the 2 states... more

Alan Brochstein thinks investors are overly excited about the recent rescheduling announcement, which he says is really no news at... more

Alex Carchidi updates us on the psychedelic sector and what critical catalysts are approaching (1:30). Why Compass Pathways, Cybin, and... more

A rundown of reasons to be hopeful and some compelling advice from some of our favorite 2023 conversations. Why Chris... more

Nick Gastevich, aka CannaVestments, talks Q3 cannabis efforts; avoiding dilution, equity raises or adding further debt (2:30). Navigating the industry... more

TerrAscend's Executive Chairman Jason Wild returns. Focused on not spreading itself too thin ("we'd rather be more focused, spend more... more

Do ETFs make sense for everyone? ETF expert Rob Isbitts discusses his thesis on cannabis ETFs and the importance of... more

Chris DeMuth talks about investing in the cannabis industry (1:30) legalization, SAFE banking and whether the investment community cares (9:00)... more

Jesse Redmond returns to discuss why it's ok to be bullish on the cannabis industry (4:30) political catalysts, 280E and... more

Emily Paxhia discusses recent positive news for the industry and its accompanying rally (2:00), the long-term play in cannabis, especially... more

Alan Brochstein and Julian Lin discuss investing in cannabis stocks and mistakes made along the way (3:00). Why companies should... more

Enosis Therapeutics combines virtual reality with psychedelic psychotherapy protocols. Founders Dr. Prashanth Puspanathan and Agnieszka Sekula discuss why VR makes... more

Paul Trowe talks about going from crypto to cannabis by founding Herban Bud in Austin, Texas (5:00). Breaking down cannabinoids... more

Analyst Alex Carchidi returns to update investors on the psychedelics industry. This is the full conversation of an interview originally... more

Derek Du Chesne and Dr. Sam Zand founded Better U and today discuss getting into ketamine therapy (4:00), psychedelics gaining... more

MariMed (MRMD) CEO Jon Levine discusses steady growth and the cannabis retail market.(8:30) - Owning real estate and consecutive quarters... more

(3:00) - Headwaters' Nick Brandis on one of the largest cannabis cultivators you've never heard of(8:00) - Why greenhouses will... more

Alan Brochstein is back to share his cannabis investing insights.(2:50) - 420 Investor's origin story(8:30) - Cannabis investing timeline -... more

4Front Ventures' (FFNTF) Brandon Mills joins us to discuss how they're making it work in an incredibly challenging environment. In... more

Psychedelics are being pulled into the mainstream by medical research (9:00). Filament Health CEO Benjamin Lightburn on Psilocybin and why... more

Outlining the cannabis industry's Haves (companies that have been able to raise capital) and The Have Nots (no ability to... more

David Goubert, recently minted CEO and President of Ayr Wellness (AYRWF), discuses coming on board (3:00), working through debt, strategizing... more

Hirsh Jain joins Jeffrey Schultz to break down what's happening - and what's not - in the New York and... more

Imran Khan is Executive Director of the Berkeley Center for the Science of Psychedelics. With psychedelics, there's more that we... more

Where Jerry Derevyanny, a partner at Bengal Capital, believes we can find the most value from cannabis stocks. (3:35) Why... more

Dr. Julie Holland is a psychiatrist/psychopharmacologist, author, medical advisor to MAPS, and a medical monitor for several clinical studies. (3:30)... more

Ascend (AAWH) has been one of the MSOs that analysts have been writing about on Seeking Alpha and championing on... more

Rob Sechrist discusses starting Pelorus Equity Group and its Fund, a privately held mortgage real estate investment trust (mREIT) (2:39)... more

Mental health is perhaps the biggest health issue facing society and traditional medicine has been limited in its success treating... more

The first ever cannabis investing podcast roundtable discussion with Bryan Fields + Kellan Finney, Benzinga's Javier Hasse and Patrick Aylward.... more

Organigram (OGI) CEO Beena Goldenberg talks the changing (and challenging) Canadian cannabis market. Balance sheet strength and British American Tobacco's... more

Cannabis stocks are really cheap, but Alan Brochstein is worried about 3 things. We discuss sector debt and optimal cannabis... more

Red Light Holland CEO Todd Shapiro talks recreational approach to psilocybin and its focus on near-term revenue - a rarity... more

Wana Brands CEO Nancy Whiteman on being one of the top edible brands in North America and how they grew... more

Nick Gastevich, aka CannaVestments, one of our favorite commenters on Seeking Alpha, returns for a super actionable take on cannabis... more

When will capital markets catch up to the psychedelic industry? Ronan Levy, CEO and Co-Founder of Field Trip, discusses strategy... more

How should cannabis investors ride the wave of depressed valuations? Tiby Erdely, who came to cannabis from Goldman Sachs and... more

As the industry develops, lots of talk recently around cannabis consumption lounges and cannabis tourism in Colorado, Nevada and beyond.... more

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Why he's a big believer in Compass Pathways (CMPS)... more

Legal cannabis has officially hit New York. Two long-time advocates, Allan Gandelman and Kaelan Castetter, came on when New York... more

What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and... more